5 completed, 5 recruiting, 5 withdrawn, 3 terminated. 23 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 5, Recruiting 5, Withdrawn 5, Terminated 3, Unknown 3, Active not recruiting 2 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow brigatinib: new trials by email Literature Review of brigatinib trials Research Report on brigatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) Brigatinib, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-12-11 | 2025-04-24 | |
| Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer Brigatinib, Durvalumab - NSCLC, Stage III, ALK-rearrangement | Phase 2 | Withdrawn | ETOP IBCSG Partners Foundation | 2024-06-07 | 2024-10-08 | |
| Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 65 | 2022-08-18 | 2025-12-05 |
| A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. Brigatinib - Non-small Cell Lung Cancer | Phase 2 | Unknown | Yonsei University | 12 | 2022-06-01 | 2022-05-04 |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) Brigatinib 180 MG, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer, ALK Gene Mutation | Phase 2 | Active not recruiting | Intergroupe Francophone de Cancerologie Thoracique | 110 | 2022-05-18 | 2025-11-17 |
| ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma Crizotinib - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 90 | 2021-11-13 | 2024-09-20 |
| Brigatinib Before Brain Irradiation Trial (B3i Trial) Brigatinib - Brain Metastases, Lung Cancer | Phase 2 | Terminated | University of Colorado, Denver | 1 | 2020-11-17 | 2022-10-24 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors Brigatinib, Brigatinib AAF - Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors | Phase 1 / Phase 2 | Withdrawn | Takeda | 2020-09-01 | 2020-03-05 | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Recruiting | Scott R. Plotkin, MD, PhD | 109 | 2020-06-20 | 2026-11-12 |
| Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays Brigatinib - Non Small Cell Lung Cancer | Phase 2 | Unknown | JI-YOUN HAN | 35 | 2020-05-15 | 2023-09-28 |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients Brigatinib - Lung Cancer, NSCLC | Phase 2 | Active not recruiting | Fundación GECP | 33 | 2020-05-04 | 2026-02-04 |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation Osimertinib, Alectinib 150 MG, Crizotinib 250 MG - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 6000 | 2020-04-16 | 2024-10-22 |
| Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping Brigatinib, Tyrosine kinase inhibitor - NSCLC | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 118 | 2020-03-30 | 2026-06-23 |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Alectinib, Brigatinib, Carboplatin - Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2019-07-25 | 2026-04-23 |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression | Phase 2 | Withdrawn | Sameek Roychowdhury | 2019-03-20 | 2022-02-18 | |
| A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib Brigatinib - ALK-positive Advanced NSCLC | Phase 2 | Completed | Ariad Pharmaceuticals | 103 | 2019-01-31 | 2025-07-31 |
| Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Withdrawn | Fox Chase Cancer Center | 2018-12-06 | 2021-01-05 | |
| Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Brigatinib - ALK-positive Advanced NSCLC | Phase 2 | Completed | Takeda | 104 | 2018-01-29 | 2024-05-08 |
Showing 20 of 23. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Lymphoma, Large-Cell, Anaplastic (4) · Lung Neoplasms (3) · Brain Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Pancreatic Ductal (1) · Ependymoma (1) · Gastrointestinal Neoplasms (1) · Granuloma, Plasma Cell (1) · Meningioma (1) · Neoplasm Metastasis (1) · Neurofibromatosis 2 (1) · Neuroma, Acoustic (1)
Ariad Pharmaceuticals (3) · Hunan Province Tumor Hospital (2) · Takeda (2) · Criterium, Inc. (1) · ETOP IBCSG Partners Foundation (1) · Fondazione per la Medicina Personalizzata (1) · Fox Chase Cancer Center (1) · Fundación GECP (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · JI-YOUN HAN (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Princess Maxima Center for Pediatric Oncology (1) · Sameek Roychowdhury (1)
United States (7) · France (4) · China (3) · Italy (3) · South Korea (3) · Spain (3) · Canada (2) · Germany (2) · Japan (2) · Netherlands (2) · Australia (1) · Austria (1) · Hong Kong (1) · Poland (1) · Sweden (1)
Yongchang Zhang, MD (2) · Andrea Botticelli (1) · Chad Rusthoven, MD (1) · Jessica J Lin (1) · Mariano Provencio, MD (1) · Michel Zwaan, Prof (1) · Paolo Marchetti (1) · Rafal Dziadziuszko, MD (1) · Robert C. Grant, MD (1) · Salah-Eddin Al-Batran, Prof. (1) · Sameek Roychowdhury, MD (1)
PMID 29768119, PMID 41110382, PMID 23411383, PMID 27836716, PMID 31125274, PMID 33039599, PMID 33569983, PMID 34182952, PMID 36036294, PMID 36096442, PMID 38904277, PMID 41023484, PMID 41963505
2018 (2), 2019 (1), P30CA016058 (1), P30CA046934 (1), U10CA180868 (1)